Marshall Wace
ATNM icon

Marshall Wace’s Actinium Pharmaceuticals ATNM Stock Holding History

Marshall Wace’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,336
Closed -$42.1K – 2946
2025
Q3 		$42.1K Sell
26,336
-71,787
-73% -$117K ﹤0.01% 2738
2025
Q2 		$137K Buy
+98,123
New +$147K ﹤0.01% 2506
2024
Q4 		– Sell
-32,934
Closed -$61.9K – 2569
2024
Q3 		$61.9K Sell
32,934
-223,092
-87% -$882K ﹤0.01% 2410
2024
Q2 		$1.89M Buy
256,026
+103,557
+68% +$853K ﹤0.01% 1399
2024
Q1 		$1.19M Buy
+152,469
New +$980K ﹤0.01% 1583
2023
Q2 		– Sell
-74,355
Closed -$703K – 2452
2023
Q1 		$703K Buy
74,355
+51,896
+231% +$548K ﹤0.01% 1963
2022
Q4 		$239K Buy
+22,459
New +$228K ﹤0.01% 2645
2021
Q4 		– Sell
-22,469
Closed -$199K – 3840
2021
Q3 		$199K Buy
+22,469
New +$156K ﹤0.01% 2804
2021
Q2 		– Sell
-13,019
Closed -$99K – 2632
2021
Q1 		$99K Sell
13,019
-9,823
-43% -$83.4K ﹤0.01% 2358
2020
Q4 		$178K Buy
+22,842
New +$248K ﹤0.01% 1756

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's ATNM Position: Q4 2025 in Review

Marshall Wace sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 26,336 shares — an estimated $42.1K sold.

Marshall Wace first reported a position in ATNM in Q4 2020 and held it in 10 quarters. The position peaked at $1.89M in Q2 2024. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.

  • Marshall Wace reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 26,336 Actinium Pharmaceuticals shares in Q4 2025, an estimated $42.1K.
  • Marshall Wace first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Marshall Wace's Actinium Pharmaceuticals position peaked at $1.89M in Q2 2024.
  • 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.